Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like Teva Wraps Up $703M Sale of Global Women’s Health Biz to CVC Capital January 31, 2018 Protalix BioTherapeutics Treatment for Ulcerative Colitis Shows Positive Data March 12, 2018 Why This Biotech, Up 300% Since May, Could be the Next Big M&A Target October 8, 2017
